{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:31:41Z","timestamp":1794000701554,"version":"4.8.0"},"reference-count":264,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) have revolutionized the management of multiple malignancies, offering durable clinical benefit in a subset of patients. However, the emergence of distinct response patterns has revealed two major challenges: primary resistance, observed in patients who fail to respond from the outset, and acquired resistance, which develops after an initial period of disease control. These two resistance phenotypes likely arise from divergent biological mechanisms, involving both tumour-intrinsic and tumour-extrinsic factors. A comprehensive understanding of these processes is essential to optimize therapeutic strategies, particularly through rational combinations of ICIs with novel immunomodulators, targeted therapies, or conventional treatments. In this review, we provide an integrative overview of the key molecular and cellular mechanisms underlying both primary and acquired resistance to ICIs, encompassing alterations in antigen presentation, interferon signalling, oncogenic and metabolic pathways, as well as immune exclusion within the tumour microenvironment. We also highlight emerging predictive biomarkers of response and resistance\u2014ranging from genomic and transcriptomic signatures to soluble immune checkpoints and non-immune circulating markers\u2014aimed at refining patient selection and guiding personalized immunotherapy. Ultimately, deciphering these mechanisms will be pivotal for designing the next generation of immune-based combinations to overcome therapeutic resistance and expand the population of patients who can benefit from immune checkpoint blockade.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1735741","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T05:23:31Z","timestamp":1772515411000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["A comprehensive review of mechanisms underlying resistance to immune checkpoint inhibitors"],"prefix":"10.3389","volume":"17","author":[{"given":"Alexandre","family":"Bertucci","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Paoli-Calmettes Institute","place":["Marseille, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaoula","family":"Taleb","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Paoli-Calmettes Institute","place":["Marseille, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilien","family":"Billon","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Paoli-Calmettes Institute","place":["Marseille, France"]},{"name":"Team Immunity and Cancer, Centre de Recherche en Canc\u00e9rologie de Marseille (CRCM), INSERM U1068, CNRS UMR 7258, Aix-Marseille University UM105 and Paoli-Calmettes Institute","place":["Marseille, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T\u00e9o","family":"Fernez","sequence":"additional","affiliation":[{"name":"Team Immunity and Cancer, Centre de Recherche en Canc\u00e9rologie de Marseille (CRCM), INSERM U1068, CNRS UMR 7258, Aix-Marseille University UM105 and Paoli-Calmettes Institute","place":["Marseille, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Rochigneux","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Paoli-Calmettes Institute","place":["Marseille, France"]},{"name":"Team Immunity and Cancer, Centre de Recherche en Canc\u00e9rologie de Marseille (CRCM), INSERM U1068, CNRS UMR 7258, Aix-Marseille University UM105 and Paoli-Calmettes Institute","place":["Marseille, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.693609","article-title":"Acquired resistance to immune checkpoint blockades: the underlying mechanisms and potential strategies","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0828","article-title":"Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer","volume":"7","author":"Anagnostou","year":"2017","journal-title":"Cancer Discov"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumours to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e000398","DOI":"10.1136\/jitc-2019-000398","article-title":"Defining tumour resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce","volume":"8","author":"Kluger","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.03.006","article-title":"Immune checkpoint inhibitors in thoracic Malignancies: review of the existing evidence by an IASLC expert panel and recommendations","volume":"15","author":"Remon","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 challenges in cancer immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30234-5","article-title":"Turning up the heat on non-immunoreactive tumours: opportunities for clinical development","volume":"21","author":"Ochoa de Olza","year":"2020","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_240837","article-title":"Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all patients","volume":"39","author":"Fares","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30407-3","article-title":"Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis","volume":"20","author":"Antonia","year":"2019","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.03.017","article-title":"Acquired resistance to immune checkpoint inhibitors","volume":"37","author":"Schoenfeld","year":"2020","journal-title":"Cancer Cell"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz003","article-title":"Novel patterns of response under immunotherapy","volume":"30","author":"Borcoman","year":"2019","journal-title":"Ann Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s13059-020-02166-1","article-title":"Clonal tracing reveals diverse patterns of response to immune checkpoint blockade","volume":"21","author":"Gu","year":"2020","journal-title":"Genome Biol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","article-title":"Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape","volume":"4","author":"Taube","year":"2012","journal-title":"Sci Transl Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/j.cell.2020.10.026","article-title":"High-spatial-resolution multi-omics sequencing via deterministic barcoding in tissue","volume":"183","author":"Liu","year":"2020","journal-title":"Cell"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-00449-x","article-title":"Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy","volume":"18","author":"Gohil","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-020-0692-4","article-title":"The mutational signature profile of known and suspected human carcinogens in mice","volume":"52","author":"Riva","year":"2020","journal-title":"Nat Genet"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-020-00730-w","article-title":"Are carcinogens direct mutagens","volume":"52","author":"Lopez-Bigas","year":"2020","journal-title":"Nat Genet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e41090","DOI":"10.7554\/eLife.41090","article-title":"Rejection of immunogenic tumour clones is limited by clonal fraction","volume":"7","author":"Gejman","year":"2018","journal-title":"Elife"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","article-title":"Allele-specific HLA loss and immune escape in lung cancer evolution","volume":"171","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30516-8","article-title":"Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis","volume":"18","author":"Turajlic","year":"2017","journal-title":"Lancet Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1032-7","article-title":"Neoantigen-directed immune escape in lung cancer evolution","volume":"567","author":"Rosenthal","year":"2019","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.immuni.2017.02.001","article-title":"Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma","volume":"46","author":"George","year":"2017","journal-title":"Immunity"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1178","article-title":"Immunotherapy resistance by inflammation-induced dedifferentiation","volume":"8","author":"Mehta","year":"2018","journal-title":"Cancer Discov"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1609874","article-title":"Acquired resistance during adoptive cell therapy by transcriptional silencing of immunogenic antigens","volume":"8","author":"Wylie","year":"2019","journal-title":"Oncoimmunology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.coi.2015.02.009","article-title":"Transport and quality control of MHC class I molecules in the early secretory pathway","volume":"34","author":"Springer","year":"2015","journal-title":"Curr Opin Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.03.075","article-title":"Genomic correlates of immune-cell infiltrates in colorectal carcinoma","volume":"15","author":"Giannakis","year":"2016","journal-title":"Cell Rep"},{"key":"B32","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and genetic properties of tumours associated with local immune cytolytic activity","volume":"160","author":"Rooney","year":"2015","journal-title":"Cell"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.2","article-title":"Acquired resistance to immunotherapy and future challenges","volume":"16","author":"Restifo","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.23469","article-title":"HLA class I loss and PD-L1 expression in lung cancer: impact on T-cell infiltration and immune escape","volume":"9","author":"Perea","year":"2018","journal-title":"Oncotarget"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3344","article-title":"Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes","volume":"33","author":"Shukla","year":"2015","journal-title":"Nat Biotechnol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3868","DOI":"10.1038\/s41467-018-06300-3","article-title":"Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA","volume":"9","author":"Paulson","year":"2018","journal-title":"Nat Commun"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0672","article-title":"Somatic HLA class I loss is a widespread mechanism of immune evasion which refines the use of tumour mutational burden as a biomarker of checkpoint inhibitor response","volume":"11","author":"Montesion","year":"2021","journal-title":"Cancer Discov"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1038\/s41467-020-15726-7","article-title":"Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition","volume":"11","author":"Lee","year":"2020","journal-title":"Nat Commun"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao4572","article-title":"Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy","volume":"359","author":"Chowell","year":"2018","journal-title":"Science"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0654-5","article-title":"Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma","volume":"25","author":"Liu","year":"2019","journal-title":"Nat Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2229-5","article-title":"Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I","volume":"581","author":"Yamamoto","year":"2020","journal-title":"Nature"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-1771","article-title":"HPV16 E5 mediates resistance to PD-L1 blockade and can be targeted with rimantadine in head and neck cancer","volume":"80","author":"Miyauchi","year":"2020","journal-title":"Cancer Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0860-1","article-title":"High systemic and tumour-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade","volume":"26","author":"Yuen","year":"2020","journal-title":"Nat Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.cell.2018.05.028","article-title":"Mitophagy in intestinal epithelial cells triggers adaptive immunity during tumourigenesis","volume":"174","author":"Ziegler","year":"2018","journal-title":"Cell"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aba5412","article-title":"Oncoprotein SND1 hijacks nascent MHC-I heavy chain to ER-associated degradation, leading to impaired CD8+ T cell response in tumour","volume":"6","author":"Wang","year":"2020","journal-title":"Sci Adv"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","article-title":"Resistance to checkpoint blockade therapy through inactivation of antigen presentation","volume":"8","author":"Sade-Feldman","year":"2017","journal-title":"Nat Commun"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/88.2.100","article-title":"Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy","volume":"88","author":"Restifo","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-199310000-00004","article-title":"Molecular mechanisms used by tumours to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I","volume":"14","author":"Restifo","year":"1993","journal-title":"J Immunother Emphasis Tumour Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1084\/jem.175.1.163","article-title":"RMA\/S cells present endogenously synthesized cytosolic proteins to class I-restricted cytotoxic T lymphocytes","volume":"175","author":"Esquivel","year":"1992","journal-title":"J Exp Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1126\/science.7863326","article-title":"Peptide specificity in the recognition of MHC class I by natural killer cell clones","volume":"267","author":"Malnati","year":"1995","journal-title":"Science"},{"key":"B51","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/s1359-6101(01)00038-7","article-title":"The roles of IFN gamma in protection against tumour development and cancer immunoediting","volume":"13","author":"Ikeda","year":"2002","journal-title":"Cytokine Growth Factor Rev"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.13.7556","article-title":"Demonstration of an interferon gamma-dependent tumour surveillance system in immunocompetent mice","volume":"95","author":"Kaplan","year":"1998","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B53","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1089\/jir.2012.0159","article-title":"A death-promoting role for ISG54\/IFIT2","volume":"33","author":"Reich","year":"2013","journal-title":"J Interferon Cytokine Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-1138","article-title":"The ICOS\/ICOSL pathway is required for optimal antitumour responses mediated by anti-CTLA-4 therapy","volume":"71","author":"Fu","year":"2011","journal-title":"Cancer Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12335","article-title":"Interdependent IL-7 and IFN-\u03b3 signalling in T-cell controls tumour eradication by combined \u03b1-CTLA-4+\u03b1-PD-1 therapy","volume":"7","author":"Shi","year":"2016","journal-title":"Nat Commun"},{"key":"B56","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","article-title":"Loss of IFN-\u03b3 Pathway genes in tumour cells as a mechanism of resistance to anti-CTLA-4 therapy","volume":"167","author":"Gao","year":"2016","journal-title":"Cell"},{"key":"B57","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","article-title":"Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations","volume":"7","author":"Shin","year":"2017","journal-title":"Cancer Discov"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx271","article-title":"Tumour CDKN2A-associated JAK2 loss and susceptibility to immunotherapy resistance","volume":"110","author":"Horn","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2984","article-title":"The genetic evolution of treatment-resistant cutaneous, acral, and uveal melanomas","volume":"27","author":"Makohon-Moore","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"e004703","DOI":"10.1136\/jitc-2022-004703","article-title":"Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR\/MSI-H gastrointestinal cancer","volume":"10","author":"Wang","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B61","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.celrep.2014.08.044","article-title":"Enhancing chemotherapy efficacy in Pten-deficient prostate tumours by activating the senescence-associated antitumour immunity","volume":"9","author":"Toso","year":"2014","journal-title":"Cell Rep"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0283","article-title":"Loss of PTEN promotes resistance to T cell-mediated immunotherapy","volume":"6","author":"Peng","year":"2016","journal-title":"Cancer Discov"},{"key":"B64","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1186\/s40425-019-0780-0","article-title":"Secondary resistance to immunotherapy associated with \u03b2-catenin pathway activation or PTEN loss in metastatic melanoma","volume":"7","author":"Trujillo","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2017.89","article-title":"Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients","volume":"30","author":"Kakavand","year":"2017","journal-title":"Mod Pathol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.05.014","article-title":"Mutant PIK3CA promotes cell growth and invasion of human cancer cells","volume":"7","author":"Samuels","year":"2005","journal-title":"Cancer Cell"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2021.02.003","article-title":"The landscape of PIK3CA mutations in colorectal cancer","volume":"20","author":"Voutsadakis","year":"2021","journal-title":"Clin Colorectal Cancer"},{"key":"B68","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1158\/0008-5472.CAN-15-1439","article-title":"STK11\/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumour microenvironment","volume":"76","author":"Koyama","year":"2016","journal-title":"Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-1236","article-title":"Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities","volume":"5","author":"Skoulidis","year":"2015","journal-title":"Cancer Discov"},{"key":"B70","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/annonc\/mdw436","article-title":"Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up","volume":"28","author":"Kadara","year":"2017","journal-title":"Ann Oncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1543","article-title":"Resistance to durvalumab and durvalumab plus tremelimumab is associated with functional STK11 mutations in patients with non-small cell lung cancer and is reversed by STAT3 knockdown","volume":"11","author":"Pore","year":"2021","journal-title":"Cancer Discov"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11020196","article-title":"The importance of STK11\/LKB1 assessment in non-small cell lung carcinomas","volume":"11","author":"Mograbi","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"B74","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-017-0471-6","article-title":"Wnt\/beta-catenin pathway: modulating anticancer immune response","volume":"10","author":"Pai","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s40425-015-0089-6","article-title":"A new paradigm for tumour immune escape: \u03b2-catenin-driven immune exclusion","volume":"3","author":"Spranger","year":"2015","journal-title":"J Immunother Cancer"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/nature25015","article-title":"Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance","volume":"553","author":"Zhang","year":"2018","journal-title":"Nature"},{"key":"B77","article-title":"Clinicopathological and prognostic significance of cyclin D1 amplification in patients with breast cancer: a meta-analysis","volume":"22","author":"He","year":"2017","journal-title":"J BUON"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12327","article-title":"KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1\/PD-L1 immunotherapy in non-small cell lung cancer","volume":"42","author":"Liu","year":"2022","journal-title":"Cancer Commun (Lond)"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1841","article-title":"Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer","volume":"24","author":"Arbour","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2021-0090","article-title":"Efficacy of immunotherapy in KRAS-mutant non-small-cell lung cancer with comutations","volume":"13","author":"Davis","year":"2021","journal-title":"Immunotherapy"},{"key":"B81","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1002\/cbin.11524","article-title":"KRAS G12V mutation upregulates PD-L1 expression via TGF-\u03b2\/EMT signalling pathway in human non-small-cell lung cancer","volume":"45","author":"Pan","year":"2021","journal-title":"Cell Biol Int"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2019.01.013","article-title":"KrasG12D mutation contributes to regulatory T cell conversion through activation of the MEK\/ERK pathway in pancreatic cancer","volume":"446","author":"Cheng","year":"2019","journal-title":"Cancer Lett"},{"key":"B83","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ccell.2019.02.008","article-title":"KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer","volume":"35","author":"Liao","year":"2019","journal-title":"Cancer Cell"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0012-z","article-title":"ARID1A deficiency promotes mutability and potentiates therapeutic antitumour immunity unleashed by immune checkpoint blockade","volume":"24","author":"Shen","year":"2018","journal-title":"Nat Med"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.cmet.2021.04.001","article-title":"Tumours exploit FTO-mediated regulation of glycolytic metabolism to evade immune surveillance","volume":"33","author":"Liu","year":"2021","journal-title":"Cell Metab"},{"key":"B86","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/s41419-022-04672-5","article-title":"YTHDF1 promotes breast cancer cell growth, DNA damage repair and chemoresistance","volume":"13","author":"Sun","year":"2022","journal-title":"Cell Death Dis"},{"key":"B87","doi-asserted-by":"publisher","first-page":"e181612","DOI":"10.1172\/JCI181612","article-title":"YTHDF1 loss in dendritic cells potentiates radiation-induced antitumour immunity via STING-dependent type I IFN production","volume":"134","author":"Wen","year":"2024","journal-title":"J Clin Invest"},{"key":"B88","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41467-022-35710-7","article-title":"Tumour-intrinsic YTHDF1 drives immune evasion and resistance to immune checkpoint inhibitors via promoting MHC-I degradation","volume":"14","author":"Lin","year":"2023","journal-title":"Nat Commun"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2698-6","article-title":"Pervasive chromosomal instability and karyotype order in tumour evolution","volume":"587","author":"Watkins","year":"2020","journal-title":"Nature"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-3962","article-title":"The tumour microenvironment innately modulates cancer progression","volume":"79","author":"Hinshaw","year":"2019","journal-title":"Cancer Res"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.01.045","article-title":"Exploiting temporal collateral sensitivity in tumour clonal evolution","volume":"165","author":"Zhao","year":"2016","journal-title":"Cell"},{"key":"B92","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cell.2021.01.002","article-title":"Meta-analysis of tumour- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition","volume":"184","author":"Litchfield","year":"2021","journal-title":"Cell"},{"key":"B93","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","article-title":"Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer","volume":"6","author":"Li","year":"2021","journal-title":"Sig Transduct Target Ther"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-09371-z","article-title":"Targeting myeloid-derived suppressor cells for premetastatic niche disruption after tumour resection","volume":"28","author":"Tang","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.immuni.2021.03.022","article-title":"Redefining macrophage and neutrophil biology in the metastatic cascade","volume":"54","author":"G\u00fc\u00e7","year":"2021","journal-title":"Immunity"},{"key":"B96","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s40425-019-0674-1","article-title":"Characterization of a whole blood assay for quantifying myeloid-derived suppressor cells","volume":"7","author":"Apodaca","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B97","doi-asserted-by":"publisher","first-page":"e002323","DOI":"10.1136\/jitc-2020-002323","article-title":"Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory\/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial","volume":"9","author":"Jim\u00e9nez-Cortegana","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01590","article-title":"Myeloid cells as clinical biomarkers for immune checkpoint blockade","volume":"11","author":"Peranzoni","year":"2020","journal-title":"Front Immunol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114354","article-title":"Targeting tumour-associated macrophages as an antitumour strategy","volume":"183","author":"Cheng","year":"2021","journal-title":"Biochem Pharmacol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/nrd.2018.169","article-title":"Targeting macrophages: therapeutic approaches in cancer","volume":"17","author":"Cassetta","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2013.154","article-title":"Macrophages stimulate gastric and colorectal cancer invasion through EGFR Y(1086), c-Src, Erk1\/2 and Akt phosphorylation and smallGTPase activity","volume":"33","author":"Cardoso","year":"2014","journal-title":"Oncogene"},{"key":"B102","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13045-017-0430-2","article-title":"Tumour-associated macrophages: from basic research to clinical application","volume":"10","author":"Yang","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0537","article-title":"Programmed cell death ligand 1 (PD-L1) signalling regulates macrophage proliferation and activation","volume":"6","author":"Hartley","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1172\/JCI137110","article-title":"Targeting tumour-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma","volume":"130","author":"Loeuillard","year":"2020","journal-title":"J Clin Invest"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.024","article-title":"Transforming growth factor-\u03b2 Signalling in immunity and cancer","volume":"50","author":"Batlle","year":"2019","journal-title":"Immunity"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aav3334","article-title":"Tumour-derived TGF-\u03b2 inhibits mitochondrial respiration to suppress IFN-\u03b3 production by human CD4+ T cells","volume":"12","author":"Dimeloe","year":"2019","journal-title":"Sci Signal"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30289","article-title":"Impaired T cell function in Malignant pleural effusion is caused by TGF-\u03b2 derived predominantly from macrophages","volume":"139","author":"Li","year":"2016","journal-title":"Int J Cancer"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2017.03.015","article-title":"Transforming growth factor-\u03b2 Signalling in regulatory T cells controls T helper-17 cells and tissue-specific immune responses","volume":"46","author":"Konkel","year":"2017","journal-title":"Immunity"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/nature25492","article-title":"TGF\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis","volume":"554","author":"Tauriello","year":"2018","journal-title":"Nature"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28181","article-title":"Necrosis in DU145 prostate cancer spheroids induces COX-2\/mPGES-1-derived PGE2 to promote tumour growth and to inhibit T cell activation","volume":"133","author":"Sha","year":"2013","journal-title":"Int J Cancer"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181b91c9c","article-title":"Tumour secretion of VEGF induces endothelial cells to suppress T cell functions through the production of PGE2","volume":"33","author":"Mulligan","year":"2010","journal-title":"J Immunother"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1612920114","article-title":"COX2\/mPGES1\/PGE2 pathway regulates PD-L1 expression in tumour-associated macrophages and myeloid-derived suppressor cells","volume":"114","author":"Prima","year":"2017","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02628-2","article-title":"The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer","volume":"69","author":"Komura","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-012-0342-8","article-title":"Multifaceted roles of PGE2 in inflammation and cancer","volume":"35","author":"Nakanishi","year":"2013","journal-title":"Semin Immunopathol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.smim.2017.12.003","article-title":"Exosome and mesenchymal stem cell cross-talk in the tumour microenvironment","volume":"35","author":"Whiteside","year":"2018","journal-title":"Semin Immunol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-0124","article-title":"Transfer of miRNA in macrophage-derived exosomes induces drug resistance in pancreatic adenocarcinoma","volume":"78","author":"Binenbaum","year":"2018","journal-title":"Cancer Res"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0178-3","article-title":"miR-21 depletion in macrophages promotes tumouricidal polarization and enhances PD-1 immunotherapy","volume":"37","author":"Xi","year":"2018","journal-title":"Oncogene"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2021.02.005","article-title":"M2 macrophage-derived exosomal microRNA-155-5p promotes the immune escape of colon cancer by downregulating ZC3H12B","volume":"20","author":"Ma","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20181170","article-title":"Neutrophils facilitate ovarian cancer premetastatic niche formation in the omentum","volume":"216","author":"Lee","year":"2019","journal-title":"J Exp Med"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2019.10.013","article-title":"Unmasking the many faces of tumour-associated neutrophils and macrophages: considerations for targeting innate immune cells in cancer","volume":"5","author":"Keeley","year":"2019","journal-title":"Trends Cancer"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1038\/nri3175","article-title":"Coordinated regulation of myeloid cells by tumours","volume":"12","author":"Gabrilovich","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.06.017","article-title":"Polarization of tumour-associated neutrophil phenotype by TGF-beta: \u201cN1\u201d versus \u201cN2\u201d TAN","volume":"16","author":"Fridlender","year":"2009","journal-title":"Cancer Cell"},{"key":"B123","doi-asserted-by":"publisher","first-page":"e1134073","DOI":"10.1080\/2162402X.2015.1134073","article-title":"Priming of neutrophils toward NETosis promotes tumour growth","volume":"5","author":"Demers","year":"2016","journal-title":"Oncoimmunology"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aak9702","article-title":"Blockade of surface-bound TGF-\u03b2 on regulatory T cells abrogates suppression of effector T cell function in the tumour microenvironment","volume":"10","author":"Budhu","year":"2017","journal-title":"Sci Signal"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-018-0004-4","article-title":"When worlds collide: Th17 and Treg cells in cancer and autoimmunity","volume":"15","author":"Knochelmann","year":"2018","journal-title":"Cell Mol Immunol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"9999","DOI":"10.1073\/pnas.1822001116","article-title":"PD-1+regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer","volume":"116","author":"Kamada","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0046-y","article-title":"Biology and regulation of IL-2: from molecular mechanisms to human therapy","volume":"18","author":"Spolski","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41392-024-01988-w","article-title":"Systemic longitudinal immune profiling identifies proliferating Treg cells as predictors of immunotherapy benefit: biomarker analysis from the phase 3 CONTINUUM and DIPPER trials","volume":"9","author":"Huang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B129","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.pharmthera.2016.04.003","article-title":"State-of-the-art of regulatory dendritic cells in cancer","volume":"164","author":"Conejo-Garcia","year":"2016","journal-title":"Pharmacol Ther"},{"key":"B130","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.semcancer.2019.07.017","article-title":"Acquired resistance to cancer immunotherapy: Role of tumour-mediated immunosuppression","volume":"65","author":"Saleh","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-015-2005-0","article-title":"Human dendritic cell subsets and function in health and disease","volume":"72","author":"O\u2019Keeffe","year":"2015","journal-title":"Cell Mol Life Sci"},{"key":"B132","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.medj.2023.04.008","article-title":"CCL19+ dendritic cells potentiate clinical benefit of anti-PD-(L)1 immunotherapy in triple-negative breast cancer","volume":"4","author":"Wu","year":"2023","journal-title":"Med"},{"key":"B133","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.semcancer.2013.12.005","article-title":"Regulation of the anti-tumour immune response by cancer-associated fibroblasts","volume":"25","author":"Harper","year":"2014","journal-title":"Semin Cancer Biol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-1384","article-title":"Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer","volume":"10","author":"Kieffer","year":"2020","journal-title":"Cancer Discov"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-3158","article-title":"NOX4 inhibition potentiates immunotherapy by overcoming cancer-associated fibroblast-mediated CD8 T-cell exclusion from tumours","volume":"80","author":"Ford","year":"2020","journal-title":"Cancer Res"},{"key":"B136","doi-asserted-by":"publisher","first-page":"4753","DOI":"10.1016\/j.cell.2021.07.020","article-title":"Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy","volume":"184","author":"Koikawa","year":"2021","journal-title":"Cell"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-4141","article-title":"Cancer-associated fibroblasts suppress CD8+ T-cell infiltration and confer resistance to immune-checkpoint blockade","volume":"82","author":"Jenkins","year":"2022","journal-title":"Cancer Res"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0044","article-title":"Mouse models for cancer immunotherapy research","volume":"8","author":"Olson","year":"2018","journal-title":"Cancer Discov"},{"key":"B139","doi-asserted-by":"publisher","first-page":"5997","DOI":"10.1038\/ncomms6997","article-title":"PD-L1hi B cells are critical regulators of humoral immunity","volume":"6","author":"Khan","year":"2015","journal-title":"Nat Commun"},{"key":"B140","doi-asserted-by":"publisher","first-page":"R32","DOI":"10.1186\/ar3736","article-title":"Interleukin-10 produced by B cells is crucial for the suppression of Th17\/Th1 responses, induction of T regulatory type 1 cells and reduction of collagen-induced arthritis","volume":"14","author":"Carter","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2014.02.020","article-title":"Mast cells as targets for immunotherapy of solid tumours","volume":"63","author":"Oldford","year":"2015","journal-title":"Mol Immunol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1016646","article-title":"Mechanism and strategies of immunotherapy resistance in colorectal cancer","volume":"13","author":"Shan","year":"2022","journal-title":"Front Immunol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.10.012","article-title":"TGF-beta directly targets cytotoxic T cell functions during tumour evasion of immune surveillance","volume":"8","author":"Thomas","year":"2005","journal-title":"Cancer Cell"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aay0555","article-title":"VEGF-A drives TOX-dependent T cell exhaustion in anti-PD-1-resistant microsatellite stable colorectal cancers","volume":"4","author":"Kim","year":"2019","journal-title":"Sci Immunol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0360","article-title":"Anti-VEGF treatment enhances CD8+ T-cell antitumour activity by amplifying hypoxia","volume":"8","author":"de Almeida","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100878","article-title":"CD8+ T cell-intrinsic IL-6 signalling promotes resistance to anti-PD-L1 immunotherapy","volume":"4","author":"Huseni","year":"2023","journal-title":"Cell Rep Med"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-311585","article-title":"IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer","volume":"67","author":"Mace","year":"2018","journal-title":"Gut"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1176574","article-title":"Prognostic role of IL-8 in cancer patients treated with immune checkpoint inhibitors: a system review and meta-analysis","volume":"13","author":"Zou","year":"2023","journal-title":"Front Oncol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S86396","article-title":"Inflammation, cytokines, the IL-17\/IL-6\/STAT3\/NF-\u03baB axis, and tumourigenesis","volume":"9","author":"Chen","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"B150","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12943-020-01234-1","article-title":"Regulatory T cells in tumour microenvironment: new mechanisms, potential therapeutic strategies and future prospects","volume":"19","author":"Li","year":"2020","journal-title":"Mol Cancer"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00475","article-title":"Prostaglanin-E2 potentiates the suppressive functions of human mononuclear myeloid-derived suppressor cells and increases their capacity to expand IL-10-producing regulatory T cell subsets","volume":"10","author":"Tomi\u0107","year":"2019","journal-title":"Front Immunol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1061394","article-title":"TGF-\u03b2: A novel predictor and target for anti-PD-1\/PD-L1 therapy","volume":"13","author":"Yi","year":"2022","journal-title":"Front Immunol"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00363-z","article-title":"Interleukins in cancer: from biology to therapy","volume":"21","author":"Briukhovetska","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0097","article-title":"Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors","volume":"3","author":"Thommen","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01909","article-title":"Not all immune checkpoints are created equal","volume":"9","author":"De Sousa Linhares","year":"2018","journal-title":"Front Immunol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1217","article-title":"Multifaceted role of BTLA in the control of CD8+ T-cell fate after antigen encounter","volume":"23","author":"Ritthipichai","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B158","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumour and microenvironment evolution during immunotherapy with nivolumab","volume":"171","author":"Riaz","year":"2017","journal-title":"Cell"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat Commun"},{"key":"B160","doi-asserted-by":"publisher","first-page":"e1261779","DOI":"10.1080\/2162402X.2016.1261779","article-title":"Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer","volume":"6","author":"Shayan","year":"2017","journal-title":"Oncoimmunology"},{"key":"B161","doi-asserted-by":"publisher","first-page":"e1564505","DOI":"10.1080\/2162402X.2018.1564505","article-title":"Tim-3\/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients","volume":"8","author":"Limagne","year":"2019","journal-title":"Oncoimmunology"},{"key":"B162","doi-asserted-by":"publisher","first-page":"e1249561","DOI":"10.1080\/2162402X.2016.1249561","article-title":"Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer","volume":"6","author":"Huang","year":"2017","journal-title":"Oncoimmunology"},{"key":"B163","doi-asserted-by":"publisher","first-page":"e120360, 120360","DOI":"10.1172\/jci.insight.120360","article-title":"Tumour-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3\/FCRL6 engagement","volume":"3","author":"Johnson","year":"2018","journal-title":"JCI Insight"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4308","article-title":"VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer","volume":"23","author":"Gao","year":"2017","journal-title":"Nat Med"},{"key":"B165","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/ni.1674","article-title":"The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells","volume":"10","author":"Yu","year":"2009","journal-title":"Nat Immunol"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0132-0","article-title":"Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumour immunity","volume":"19","author":"Zhang","year":"2018","journal-title":"Nat Immunol"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.9503","article-title":"Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE)","volume":"38","author":"Rodriguez-Abreu","year":"2020","journal-title":"JCO"},{"key":"B168","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.immuni.2022.02.005","article-title":"Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumour CD8+ T cell responses","volume":"55","author":"Banta","year":"2022","journal-title":"Immunity"},{"key":"B169","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2147\/LCTT.S173724","article-title":"Non-small cell to small cell lung cancer on PD-1 inhibitors: two cases on potential histologic transformation","volume":"9","author":"Abdallah","year":"2018","journal-title":"Lung Cancer (Auckl)"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.09.025","article-title":"Transformation to small cell lung cancer as a mechanism of resistance to immunotherapy in non-small cell lung cancer","volume":"138","author":"Bar","year":"2019","journal-title":"Lung Cancer"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-00302-4","article-title":"Non-genetic mechanisms of therapeutic resistance in cancer","volume":"20","author":"Marine","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B172","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41573-019-0044-1","article-title":"The great escape: tumour cell plasticity in resistance to targeted therapy","volume":"19","author":"Boumahdi","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0603","article-title":"Direct and indirect regulators of epithelial-mesenchymal transition-mediated immunosuppression in breast carcinomas","volume":"11","author":"Dongre","year":"2021","journal-title":"Cancer Discov"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2011.04.008","article-title":"Cell surface signalling molecules in the control of immune responses: a tide model","volume":"34","author":"Zhu","year":"2011","journal-title":"Immunity"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac033","article-title":"Ferroptosis, as the most enriched programmed cell death process in glioma, induces immunosuppression and immunotherapy resistance","volume":"24","author":"Liu","year":"2022","journal-title":"Neuro Oncol"},{"key":"B176","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.1038\/s41467-022-31764-9","article-title":"Hypoxia induces HIF1\u03b1-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy","volume":"13","author":"Ma","year":"2022","journal-title":"Nat Commun"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2714","article-title":"Hypoxia-inducible factors enhance the effector responses of CD8(+) T cells to persistent antigen","volume":"14","author":"Doedens","year":"2013","journal-title":"Nat Immunol"},{"key":"B178","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.ccell.2017.10.003","article-title":"An HIF-1\u03b1\/VEGF-A axis in cytotoxic T cells regulates tumour progression","volume":"32","author":"Palazon","year":"2017","journal-title":"Cancer Cell"},{"key":"B179","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.immuni.2020.05.001","article-title":"Single-cell RNA sequencing of tumour-infiltrating NK cells reveals that inhibition of transcription factor HIF-1\u03b1 Unleashes NK cell activity","volume":"52","author":"Ni","year":"2020","journal-title":"Immunity"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-00834-9","article-title":"Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion","volume":"22","author":"Scharping","year":"2021","journal-title":"Nat Immunol"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-020-02667-4","article-title":"Hypoxia and the phenomenon of immune exclusion","volume":"19","author":"Pietrobon","year":"2021","journal-title":"J Transl Med"},{"key":"B182","doi-asserted-by":"publisher","first-page":"e002088","DOI":"10.1136\/jitc-2020-002088","article-title":"Tumour hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck","volume":"9","author":"Zandberg","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.660944","article-title":"Hypoxia supports differentiation of terminally exhausted CD8 T cells","volume":"12","author":"Bannoud","year":"2021","journal-title":"Front Immunol"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8+ T cells differentially mediate tumour control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat Immunol"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2020.09.003","article-title":"The paradoxical roles of inflammation during PD-1 blockade in cancer","volume":"41","author":"Hill","year":"2020","journal-title":"Trends Immunol"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1543","article-title":"The intersection between tumour angiogenesis and immune suppression","volume":"25","author":"Rahma","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad1329","article-title":"Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota","volume":"350","author":"V\u00e9tizou","year":"2015","journal-title":"Science"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1126\/science.aac4255","article-title":"Commensal Bifidobacterium promotes antitumour immunity and facilitates anti-PD-L1 efficacy","volume":"350","author":"Sivan","year":"2015","journal-title":"Science"},{"key":"B189","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti\u2013PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"B190","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1053\/j.gastro.2016.11.018","article-title":"Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumour development in mice by activating toll-like receptor 4 signalling to nuclear factor-\u03baB, and up-regulating expression of microRNA-21","volume":"152","author":"Yang","year":"2017","journal-title":"Gastroenterology"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.658681","article-title":"Fusobacterium nucleatum facilitates M2 macrophage polarization and colorectal carcinoma progression by activating TLR4\/NF-\u03baB\/S100A9 cascade","volume":"12","author":"Hu","year":"2021","journal-title":"Front Immunol"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2021.1980347","article-title":"Fusobacterium nucleatum promotes colorectal cancer metastasis through miR-1322\/CCL20 axis and M2 polarization","volume":"13","author":"Xu","year":"2021","journal-title":"Gut Microbes"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.01.010","article-title":"Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumours from immune cell attack","volume":"42","author":"Gur","year":"2015","journal-title":"Immunity"},{"key":"B194","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/19490976.2021.1907272","article-title":"Butyrate-producing human gut symbiont, Clostridium butyricum, and its role in health and disease","volume":"13","author":"Stoeva","year":"2021","journal-title":"Gut Microbes"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2021.06.001","article-title":"Lactobacillus rhamnosus GG orchestrates an antitumour immune response","volume":"12","author":"Owens","year":"2021","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020368","article-title":"Immune responses raised in an experimental colon carcinoma model following oral administration of lactobacillus casei","volume":"12","author":"Aindelis","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1\u2013based immunotherapy against epithelial tumours","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.3RI0516-222R","article-title":"Microbiota\u2014myeloid cell crosstalk beyond the gut","volume":"100","author":"Gorjifard","year":"2016","journal-title":"J Leukocyte Biol"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2971-8","article-title":"The gut microbiota is associated with immune cell dynamics in humans","volume":"588","author":"Schluter","year":"2020","journal-title":"Nature"},{"key":"B200","doi-asserted-by":"publisher","first-page":"e95128, 95128","DOI":"10.1172\/jci.insight.95128","article-title":"Glycolytic requirement for NK cell cytotoxicity and cytomegalovirus control","volume":"2","author":"Mah","year":"2017","journal-title":"JCI Insight"},{"key":"B201","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1038\/s41467-019-11447-8","article-title":"LncRNA GLCC1 promotes colorectal carcinogenesis and glucose metabolism by stabilizing c-Myc","volume":"10","author":"Tang","year":"2019","journal-title":"Nat Commun"},{"key":"B202","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12943-019-1105-0","article-title":"LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer","volume":"18","author":"Wang","year":"2019","journal-title":"Mol Cancer"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.59001","article-title":"Long Noncoding RNA KCNQ1OT1 is a Prognostic Biomarker and mediates CD8+ T cell exhaustion by regulating CD155 Expression in Colorectal Cancer","volume":"17","author":"Lin","year":"2021","journal-title":"Int J Biol Sci"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-0381","article-title":"CD155T\/TIGIT signalling regulates CD8+ T-cell metabolism and promotes tumour progression in human gastric cancer","volume":"77","author":"He","year":"2017","journal-title":"Cancer Res"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1038\/nature13490","article-title":"Functional polarization of tumour-associated macrophages by tumour-derived lactic acid","volume":"513","author":"Colegio","year":"2014","journal-title":"Nature"},{"key":"B206","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41392-021-00534-2","article-title":"Mutant KRAS triggers functional reprogramming of tumour-associated macrophages in colorectal cancer","volume":"6","author":"Liu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.807271","article-title":"Targeting tryptophan catabolism in cancer immunotherapy era: challenges and perspectives","volume":"13","author":"Peyraud","year":"2022","journal-title":"Front Immunol"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12999","article-title":"Oncogenic KRAS mutations enhance amino acid uptake by colorectal cancer cells via the hippo signalling effector YAP1","volume":"15","author":"Kandasamy","year":"2021","journal-title":"Mol Oncol"},{"key":"B209","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1053\/j.gastro.2020.08.016","article-title":"In colorectal cancer cells with mutant KRAS, SLC25A22-mediated glutaminolysis reduces DNA demethylation to increase WNT signalling, stemness, and drug resistance","volume":"159","author":"Wong","year":"2020","journal-title":"Gastroenterology"},{"key":"B210","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.immuni.2021.05.003","article-title":"Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumours","volume":"54","author":"Xu","year":"2021","journal-title":"Immunity"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N Engl J Med"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.09.020","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"184","author":"Morad","year":"2021","journal-title":"Cell"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0392-8","article-title":"Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response","volume":"560","author":"Chen","year":"2018","journal-title":"Nature"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1097\/PAP.0000000000000162","article-title":"Assessing tumour-infiltrating lymphocytes in solid tumours: A practical review for pathologists and proposal for a standardized method from the international immunooncology biomarkers working group: part 1: assessing the host immune response, TILs in invasive breast carcinoma and ductal carcinoma in situ, metastatic tumour deposits and areas for further research","volume":"24","author":"Hendry","year":"2017","journal-title":"Adv Anat Pathol"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-1","article-title":"The immune score as a new possible approach for the classification of cancer","volume":"10","author":"Galon","year":"2012","journal-title":"J Transl Med"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30789-X","article-title":"International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study","volume":"391","author":"Pag\u00e8s","year":"2018","journal-title":"Lancet"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.2477","article-title":"Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma","volume":"34","author":"Daud","year":"2016","journal-title":"J Clin Oncol"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1832348","article-title":"Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions","volume":"9","author":"Incorvaia","year":"2020","journal-title":"OncoImmunology"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.670827","article-title":"Soluble BTN2A1 is a potential prognosis biomarker in pre-treated advanced renal cell carcinoma","volume":"12","author":"Billon","year":"2021","journal-title":"Front Immunol"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101686","article-title":"Soluble Tim-3 serves as a tumour prognostic marker and therapeutic target for CD8+ T cell exhaustion and anti-PD-1 resistance","volume":"5","author":"Chen","year":"2024","journal-title":"Cell Rep Med"},{"key":"B222","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13046-025-03293-y","article-title":"Soluble TIM-3, likely produced by myeloid cells, predicts resistance to immune checkpoint inhibitors in metastatic clear cell renal cell carcinoma","volume":"44","author":"Pourmir","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33610","article-title":"Serum levels of soluble B and T lymphocyte attenuator predict overall survival in patients undergoing immune checkpoint inhibitor therapy for solid Malignancies","volume":"149","author":"Gorgulho","year":"2021","journal-title":"Intl J Cancer"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad216.004","article-title":"Circulating KIM-1 is a minimally invasive biomarker correlated with treatment response to nivolumab in patients with metastatic renal cell carcinoma","volume":"28","author":"Xu","year":"2023","journal-title":"Oncologist"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.007","article-title":"Circulating kidney injury molecule-1 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell carcinoma","volume":"36","author":"Rini","year":"2025","journal-title":"Ann Oncol"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.1126\/science.aay9189","article-title":"The human tumour microbiome is composed of tumour type-specific intracellular bacteria","volume":"368","author":"Nejman","year":"2020","journal-title":"Science"},{"key":"B227","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.cell.2019.07.008","article-title":"Tumour microbiome diversity and composition influence pancreatic cancer outcomes","volume":"178","author":"Riquelme","year":"2019","journal-title":"Cell"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2095-1","article-title":"Microbiome analyses of blood and tissues suggest cancer diagnostic approach","volume":"579","author":"Poore","year":"2020","journal-title":"Nature"},{"key":"B229","doi-asserted-by":"publisher","first-page":"100530","DOI":"10.1016\/j.medj.2024.10.007","article-title":"Effects of gut microbiota on immune checkpoint inhibitors in multi-cancer and as microbial biomarkers for predicting therapeutic response","volume":"6","author":"Lin","year":"2025","journal-title":"Med"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1206953","article-title":"Peripheral blood CD3+HLADR+ cells and associated gut microbiome species predict response and overall survival to immune checkpoint blockade","volume":"14","author":"Gorgulho","year":"2023","journal-title":"Front Immunol"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-1545","article-title":"Analysis of immune signatures in longitudinal tumour samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade","volume":"6","author":"Chen","year":"2016","journal-title":"Cancer Discov"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00619-z","article-title":"B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome","volume":"19","author":"Fridman","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.3390\/metabo9060106","article-title":"Tackling the complexity of the exposome: considerations from the gunma university initiative for advanced research (GIAR) exposome symposium","volume":"9","author":"Zhang","year":"2019","journal-title":"Metabolites"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2024.108078","article-title":"Identification of the key DNA damage response genes for predicting immunotherapy and chemotherapy efficacy in lung adenocarcinoma based on bulk, single-cell RNA sequencing, and spatial transcriptomics","volume":"171","author":"Sun","year":"2024","journal-title":"Comput Biol Med"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.5356","article-title":"Deep learning model for predicting immunotherapy response in advanced non-small cell lung cancer","volume":"11","author":"Rakaee","year":"2025","journal-title":"JAMA Oncol"},{"key":"B236","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s44324-024-00007-4","article-title":"Potential roles of sex-linked differences in obesity and cancer immunotherapy: revisiting the obesity paradox","volume":"2","author":"Vick","year":"2024","journal-title":"NPJ Metab Health Dis"},{"key":"B237","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.ccell.2022.06.005","article-title":"Sex and cancer immunotherapy: Current understanding and challenges","volume":"40","author":"Pala","year":"2022","journal-title":"Cancer Cell"},{"key":"B238","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41467-017-02630-w","article-title":"DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer","volume":"9","author":"Luo","year":"2018","journal-title":"Nat Commun"},{"key":"B239","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.cell.2017.10.022","article-title":"Epigenetic therapy ties MYC depletion to reversing immune evasion and treating lung cancer","volume":"171","author":"Topper","year":"2017","journal-title":"Cell"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30934-X","article-title":"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial","volume":"395","author":"Gutzmer","year":"2020","journal-title":"Lancet"},{"key":"B241","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s40425-019-0627-8","article-title":"Metabolic stress in cancer cells induces immune escape through a PI3K-dependent blockade of IFN\u03b3 receptor signalling","volume":"7","author":"Marijt","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B242","doi-asserted-by":"publisher","DOI":"10.1038\/nature23465","article-title":"CDK4\/6 inhibition triggers anti-tumour immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature"},{"key":"B243","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02593-0","article-title":"The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumours and hematologic cancers: a phase 1 trial","volume":"29","author":"Luke","year":"2023","journal-title":"Nat Med"},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02135-4","article-title":"Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China","volume":"404","author":"Wu","year":"2024","journal-title":"Lancet"},{"key":"B245","doi-asserted-by":"publisher","first-page":"4091","DOI":"10.1038\/s41467-024-48479-8","article-title":"CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials","volume":"15","author":"Segal","year":"2024","journal-title":"Nat Commun"},{"key":"B246","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"B247","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz1863","article-title":"Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumours","volume":"12","author":"Park","year":"2020","journal-title":"Sci Transl Med"},{"key":"B248","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.0546","article-title":"Association between KRAS variant status and outcomes with first-line immune checkpoint inhibitor-based therapy in patients with advanced non-small-cell lung cancer","volume":"7","author":"Sun","year":"2021","journal-title":"JAMA Oncol"},{"key":"B249","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2009","article-title":"Defining effective combinations of immune checkpoint blockade and oncolytic virotherapy","volume":"21","author":"Rojas","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B250","doi-asserted-by":"publisher","first-page":"e005640","DOI":"10.1136\/jitc-2022-005640","article-title":"Phase I\/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer","volume":"11","author":"Monge","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B251","doi-asserted-by":"publisher","first-page":"e003760","DOI":"10.1136\/jitc-2021-003760","article-title":"Live attenuated bacterium limits cancer resistance to CAR-T therapy by remodeling the tumour microenvironment","volume":"10","author":"Guo","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B252","doi-asserted-by":"publisher","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"B253","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1001\/jamaoncol.2018.4051","article-title":"Combining immune checkpoint blockade and tumour-specific vaccine for patients with incurable human papillomavirus 16-related cancer: A phase 2 clinical trial","volume":"5","author":"Massarelli","year":"2019","journal-title":"JAMA Oncol"},{"key":"B254","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-021-00636-7","article-title":"Single-cell analyses reveal the clonal and molecular aetiology of Flt3L-induced emergency dendritic cell development","volume":"23","author":"Lin","year":"2021","journal-title":"Nat Cell Biol"},{"key":"B255","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-018-0254-6","article-title":"A designer self-assembled supramolecule amplifies macrophage immune responses against aggressive cancer","volume":"2","author":"Kulkarni","year":"2018","journal-title":"Nat BioMed Eng"},{"key":"B256","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1126\/science.abf3363","article-title":"Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients","volume":"371","author":"Davar","year":"2021","journal-title":"Science"},{"key":"B257","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00669-w","article-title":"Manganese salts function as potent adjuvants","volume":"18","author":"Zhang","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B258","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/cncr.32522","article-title":"Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy","volume":"126","author":"Pires da Silva","year":"2020","journal-title":"Cancer"},{"key":"B259","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb0152","article-title":"Uncoupling interferon signalling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma","volume":"12","author":"Kalbasi","year":"2020","journal-title":"Sci Transl Med"},{"key":"B260","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0337-2","article-title":"The future of cancer immunotherapy: microenvironment-targeting combinations","volume":"30","author":"Murciano-Goroff","year":"2020","journal-title":"Cell Res"},{"key":"B261","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.ccell.2018.03.017","article-title":"Multi-stage differentiation defines melanoma subtypes with differential vulnerability to drug-induced iron-dependent oxidative stress","volume":"33","author":"Tsoi","year":"2018","journal-title":"Cancer Cell"},{"key":"B262","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02172","article-title":"Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma","volume":"42","author":"Hamid","year":"2024","journal-title":"J Clin Oncol"},{"key":"B263","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00492","article-title":"How can immune checkpoint inhibitors cause hyperprogression in solid tumours","volume":"11","author":"Denis","year":"2020","journal-title":"Front Immunol"},{"key":"B264","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-020-00425-y","article-title":"Pseudoprogression and hyperprogression as new forms of response to immunotherapy","volume":"34","author":"Frelaut","year":"2020","journal-title":"BioDrugs"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1735741\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T05:23:34Z","timestamp":1772515414000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1735741\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":264,"alternative-id":["10.3389\/fimmu.2026.1735741"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1735741","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"article-number":"1735741"}}